Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | OGFRL1 | Q5TC84 | 15/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004475 | 1.00 | MAPK1 (0.55) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL852565 | 1.00 | MAPK1 (0.55) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL852564 | 1.00 | MAPK1 (0.55) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL15467269 | 1.00 | MAPK1 (0.55) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL15842208 | 0.98 | MAPK1 (0.53) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL15842209 | 0.98 | MAPK1 (0.53) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL853902 | 0.96 | MAPK1 (0.50) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL853901 | 0.96 | MAPK1 (0.50) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL15680039 | 0.85 | MAPK1 (0.48) | MAPK1OGFRL1OPRL1OPRM1OPRK1 | |
| SCHEMBL15467588 | 0.85 | MAPK1 (0.48) | MAPK1OGFRL1OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10118927-B2 | Substituted piperidin-4-amino-type compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-11-06 | — | — | US | disclosed |
| US-9963458-B2 | Indole and indoline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9598447-B2 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2654751-B1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA LP (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2797912-B1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA LP (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9090618-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9040533-B2 | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040533-B2 | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-01-08 | — | — | US | disclosed |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014102588-A2 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QDPR, P2RX5, P2RX1 | MAPK1 2578/4885OGFRL1 1197/4885OPRL1 15/4885 |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | H1-0, H1-3, CACNA1A | MAPK1 2772/4885OGFRL1 2889/4885OPRL1 181/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | MAPK1 4045/4885OGFRL1 2320/4885OPRL1 68/4885 |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | OPRD1, OPRL1, P2RX4 | MAPK1 4053/4885OGFRL1 2168/4885OPRL1 2/4885 |
| US-10118927-B2 | Substituted piperidin-4-amino-type compounds and uses thereof | OPRD1, OPRL1, P2RX4 | MAPK1 4053/4885OGFRL1 2168/4885OPRL1 2/4885 |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | P2RX4, P2RX1, P2RX5 | MAPK1 1098/4885OGFRL1 1431/4885OPRL1 71/4885 |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QSOX1, OPRK1, OPRD1 | MAPK1 2649/4885OGFRL1 59/4885OPRL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.